Therapeutic | Mepolizumab |
Target | IL5 |
Heavy Chain | QVTLRESGPALVKPTQTLTLTCTVSGFSLTSYSVHWVRQPPGKGLEWLGVIWASGGTDYNSALMSRLSISKDTSRNQVVLTMTNMDPVDTATYYCARDPPSSLLRLDYWGRGTPVTVSS |
Light Chain | DIVMTQSPDSLAVSLGERATINCKSSQSLLNSGNQKNYLAWYQQKPGQPPKLLIYGASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQNVHSFPFTFGGGTKLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 1999 |
INN Year Recommended | 2000 |
Companies Involved | GlaxoSmithKline, McMaster University, National Institute of Allergy and Infectious Diseases |
Conditions Approved | Asthma, Churg-Strauss syndrome |
Conditions Active | Chronic obstructive pulmonary disease, Hypereosinophilic syndrome, Nasal polyps, Atopic dermatitis, Eosinophilic oesophagitis |
Conditions Discontinued | na |
Notes |